In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...